 |
October 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
October 15, 2020 - NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers
Read
October 5, 2020 - Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer
Read
September 8, 2020 - Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Read
August 19, 2020 - Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Read
August 6, 2020 - Puma Biotechnology Reports Second Quarter 2020 Financial Results
Read
July 27, 2020 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
Read
July 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 16, 2020 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Read
May 7, 2020 - Puma Biotechnology Reports First Quarter 2020 Financial Results
Read
May 7, 2020 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Read
May 6, 2020 - Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
Read
April 30, 2020 - Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Read
April 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read
March 25, 2020 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read
February 28, 2020 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read
February 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read
February 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read
February 5, 2020 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Read
|
|
Upcoming Events
Nov. 5, 2020 - Puma Biotechnology 3Q-2020 Financial Results Conference Call
More
Past Events
Sept. 15, 2020 - H.C. Wainwright 22nd Annual Global Investment Conference.
More
Aug. 6, 2020 - Puma Biotechnology 2Q-2020 Financial Results Conference Call
More
May 13, 2020 - BofA Securities Health Care Conference 2020
More
May 7, 2020 - Puma Biotechnology 1Q-2020 Financial Results Conference Call
More
March 4, 2020 - Cowen and Company 40th Annual Health Care Conference
More
Feb. 20, 2020 - Puma Biotechnology 4Q-2019 Financial Results Conference Call
More
Jan. 15, 2020 - 38th Annual J.P. Morgan Healthcare Conference
More
|
Annual Report Archives
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com
Business Development:
info@pumabiotechnology.com
Investor Relations:
ir@pumabiotechnology.com
Follow Us:
|
